Completed PHASE3 INTERVENTIONAL 2-arm NCT02396316

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (VEGA)

A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

Sponsor: Bayer

Conditions Glaucoma, Neovascular

Interventions Aflibercept (Eylea, BAY 86-5321) Sham Injection

Updated 8 times since 2017 Last updated: Aug 17, 2017 Started: Apr 2, 2015 Primary completion: Jun 16, 2016 Completion: Sep 6, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Glaucoma, Neovascular and is currently completed. Bayer leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Regeneron Pharmaceuticals

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amagasaki, Japan , Bunkyo-ku, Japan , Chūō, Japan , Gifu, Japan , Himeji, Japan , Hirakata, Japan , Izumo, Japan , Kanazawa, Japan , Kawasaki, Japan , Kobe, Japan and 9 more locations